Highlights

  • Entropy Neurodynamics (ASX: ENP) received an independent DSMB recommendation to advance its Phase 2 TRP-8803 trial in Binge Eating Disorder to Cohort 2 with no protocol modifications, following zero serious adverse reactions in Cohort 1.
  • The DSMB endorsed the 60-minute infusion regimen for Cohort 2, reduced from the 140-minute Cohort 1 regimen, representing meaningful progress toward a commercially feasible treatment duration.
  • Topline Cohort 1 efficacy results are expected in early July 2026, with Cohort 2 dosing expected to complete in Q3 CY2026 and results anticipated in Q4 CY2026.

 

 

For clinical-stage biotechnology companies operating at the frontier of psychedelic medicine, independent safety board endorsements represent more than administrative milestones — they constitute meaningful de-risking events that shift the probability distribution of eventual regulatory and commercial outcomes. Entropy Neurodynamics Limited (ASX:ENP) achieved exactly this on 15 June 2026, when its independent Data Safety Monitoring Board completed its review of Cohort 1 safety data from the Phase 2 TRP-8803 trial and recommended progression to Cohort 2 without any protocol modifications.

ENP shares fell 3.23% to A$0.030 on the day — a movement that may reflect broader market dynamics for micro-cap biotechnology stocks rather than a specific negative reaction to the announcement's content, which was uniformly positive from a clinical development perspective.

What the DSMB Found in Cohort 1

Cohort 1 enrolled six participants, each receiving two administrations of TRP-8803 — Entropy's proprietary formulation of intravenously infused psilocin — delivered 14 days apart in conjunction with supportive psychotherapy. All six participants completed both dosing sessions, a 100% completion rate that in itself is a noteworthy outcome for a trial involving a psychedelic compound in a clinically supervised setting. The DSMB's review found no Serious Adverse Reactions, no Suspected Unexpected Serious Adverse Reactions, and no discontinuations attributable to safety events.

Most adverse reactions observed were assessed as mild or moderate in severity. One Grade 3 adverse event was reported, but the DSMB characterised this as consistent with the known pharmacology of psilocin and noted that it was managed per protocol. In clinical trial terminology, a Grade 3 event is severe but not life-threatening or disabling — and when it falls within the expected pharmacological profile of a drug candidate and is managed as planned, it does not typically constitute a safety signal requiring protocol modification.

The 60-Minute Regimen: Clinical and Commercial Significance

One of the more technically significant aspects of the DSMB recommendation is the selection of the 60-minute infusion regimen for Cohort 2. Cohort 1 used a longer protocol: a 20-minute loading dose followed by a 120-minute maintenance infusion, for a total administration time of 140 minutes. From three protocol-specified options, the DSMB has recommended that Cohort 2 proceed with a 20-minute loading dose followed by a 40-minute maintenance infusion — a total of 60 minutes.

This matters commercially. One of the most significant limitations of oral psilocybin treatments is their duration: a typical oral psilocybin session can span eight to ten hours, creating substantial demands on clinical infrastructure, therapist time, and patient scheduling. A 60-minute intravenous administration window, if it proves clinically effective in Cohort 2, would represent a dramatic compression of the treatment burden — potentially making psychedelic-assisted therapy accessible in outpatient or day-procedure settings rather than requiring dedicated extended-care environments.

TRP-8803's Differentiated Design

Entropy's approach with TRP-8803 is built around addressing the limitations of oral psilocybin through intravenous delivery of psilocin, which is the active metabolite that oral psilocybin converts into following ingestion. By delivering psilocin directly via IV infusion, the company eliminates the variable and unpredictable pharmacokinetics of the oral route — where gut absorption, individual metabolism rates, and food intake all affect onset timing and exposure levels.

TRP-8803 is designed to provide a 15-minute onset, a 1 to 2 hour therapeutic window, precise control of blood concentration levels, and adjustability or reversibility during dosing if clinically warranted. These attributes make the treatment far more compatible with structured clinical workflows and reduce the safety management complexity associated with oral psychedelic administration.

Upcoming Efficacy Data and the Path Forward

While the DSMB's safety clearance confirms that TRP-8803 is well-tolerated in the Cohort 1 population, the next major inflection point for Entropy's clinical programme is the topline efficacy data from Cohort 1, expected in early July 2026. This will represent the first published look at clinical outcomes from what the company describes as the world's first IV-psilocin study in Binge Eating Disorder. Efficacy metrics will likely centre on changes in binge eating episode frequency, patient-reported psychological measures, and any biomarkers tracked within the trial design.

Cohort 2 is fully recruited and ready to commence dosing, with completion expected by the end of Q3 CY2026 and topline results anticipated in Q4 CY2026. The progression of both cohorts represents a steady cadence of data readouts over the next two to three quarters, providing multiple opportunities for the market to reassess the programme's clinical viability.